Aclaris Therapeutics ACRS Stock
Aclaris Therapeutics Price Chart
Aclaris Therapeutics ACRS Financial and Trading Overview
| Aclaris Therapeutics stock price | 4.27 USD |
| Previous Close | 4.39 USD |
| Open | 4.34 USD |
| Bid | 3.13 USD x 200 |
| Ask | 5.22 USD x 200 |
| Day's Range | 4.07 - 4.41 USD |
| 52 Week Range | 1.74 - 6.6 USD |
| Volume | 7.02M USD |
| Avg. Volume | 2.25M USD |
| Market Cap | 628.54M USD |
| Beta (5Y Monthly) | 0.882 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.18 USD |
ACRS Valuation Measures
| Enterprise Value | 538.83M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.423806 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 76.47393 |
| Price/Book (mrq) | 4.7923684 |
| Enterprise Value/Revenue | 65.559 |
| Enterprise Value/EBITDA | -6.3 |
Trading Information
Aclaris Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.882 |
| 52-Week Change | 138.58% |
| S&P500 52-Week Change | 14.57% |
| 52 Week High | 6.6 USD |
| 52 Week Low | 1.74 USD |
| 50-Day Moving Average | 5.71 USD |
| 200-Day Moving Average | 4.45 USD |
ACRS Share Statistics
| Avg. Volume (3 month) | 2.25M USD |
| Avg. Daily Volume (10-Days) | 2.85M USD |
| Shares Outstanding | 147.2M |
| Float | 101.17M |
| Short Ratio | 7.49 |
| % Held by Insiders | 2.18% |
| % Held by Institutions | 83.99% |
| Shares Short | 16.08M |
| Short % of Float | 12.40% |
| Short % of Shares Outstanding | 10.91% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1469.49% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.98% |
| Return on Equity (ttm) | -59.096% |
Income Statement
| Revenue (ttm) | 8.22M USD |
| Revenue Per Share (ttm) | 0.06 USD |
| Quarterly Revenue Growth (yoy) | -8.30% |
| Gross Profit (ttm) | -62275000 USD |
| EBITDA | -85525000 USD |
| Net Income Avi to Common (ttm) | -75738000 USD |
| Diluted EPS (ttm) | -0.58 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 91.56M USD |
| Total Cash Per Share (mrq) | 0.62 USD |
| Total Debt (mrq) | 1.85M USD |
| Total Debt/Equity (mrq) | 1.49 USD |
| Current Ratio (mrq) | 3.462 |
| Book Value Per Share (mrq) | 0.891 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -62059000 USD |
| Levered Free Cash Flow (ttm) | -41970624 USD |
Profile of Aclaris Therapeutics
| Country | United States |
| State | PA |
| City | Wayne |
| Address | 701 Lee Road |
| ZIP | 19087 |
| Phone | 484 324 7933 |
| Website | https://www.aclaristx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 69 |
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Q&A For Aclaris Therapeutics Stock
What is a current ACRS stock price?
Aclaris Therapeutics ACRS stock price today per share is 4.27 USD.
How to purchase Aclaris Therapeutics stock?
You can buy ACRS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aclaris Therapeutics?
The stock symbol or ticker of Aclaris Therapeutics is ACRS.
Which industry does the Aclaris Therapeutics company belong to?
The Aclaris Therapeutics industry is Biotechnology.
How many shares does Aclaris Therapeutics have in circulation?
The max supply of Aclaris Therapeutics shares is 147.2M.
What is Aclaris Therapeutics Price to Earnings Ratio (PE Ratio)?
Aclaris Therapeutics PE Ratio is now.
What was Aclaris Therapeutics earnings per share over the trailing 12 months (TTM)?
Aclaris Therapeutics EPS is -0.58 USD over the trailing 12 months.
Which sector does the Aclaris Therapeutics company belong to?
The Aclaris Therapeutics sector is Healthcare.
Aclaris Therapeutics ACRS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27477.31 USD — |
+1.05
|
7.04B USD — | 27223.49 USD — | 27544.06 USD — | — - | 7.04B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13524.02 USD — |
+1.07
|
— — | 13397.04 USD — | 13557.29 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7022.12 USD — |
+1.07
|
— — | 6892.36 USD — | 7043.1 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1320 USD — |
+1.33
|
— — | 1298.21 USD — | 1322.56 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
33942.38 USD — |
+1.05
|
— — | 33628.84 USD — | 34024.84 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
